|
Gene: YTHDF2 |
Gene summary for YTHDF2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | YTHDF2 | Gene ID | 51441 |
Gene name | YTH N6-methyladenosine RNA binding protein 2 | |
Gene Alias | CAHL | |
Cytomap | 1p35.3 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9Y5A9 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51441 | YTHDF2 | LZE4T | Human | Esophagus | ESCC | 3.85e-15 | 2.06e-01 | 0.0811 |
51441 | YTHDF2 | LZE5T | Human | Esophagus | ESCC | 2.03e-03 | -1.11e-01 | 0.0514 |
51441 | YTHDF2 | LZE7T | Human | Esophagus | ESCC | 1.19e-12 | 1.04e+00 | 0.0667 |
51441 | YTHDF2 | LZE8T | Human | Esophagus | ESCC | 6.20e-06 | 2.75e-01 | 0.067 |
51441 | YTHDF2 | LZE20T | Human | Esophagus | ESCC | 6.14e-03 | 1.79e-01 | 0.0662 |
51441 | YTHDF2 | LZE22T | Human | Esophagus | ESCC | 1.40e-03 | 5.54e-01 | 0.068 |
51441 | YTHDF2 | LZE24T | Human | Esophagus | ESCC | 2.35e-16 | 6.82e-01 | 0.0596 |
51441 | YTHDF2 | LZE6T | Human | Esophagus | ESCC | 5.35e-04 | 2.61e-01 | 0.0845 |
51441 | YTHDF2 | P2T-E | Human | Esophagus | ESCC | 6.41e-48 | 1.26e+00 | 0.1177 |
51441 | YTHDF2 | P4T-E | Human | Esophagus | ESCC | 1.34e-27 | 7.27e-01 | 0.1323 |
51441 | YTHDF2 | P5T-E | Human | Esophagus | ESCC | 7.73e-19 | 5.21e-01 | 0.1327 |
51441 | YTHDF2 | P8T-E | Human | Esophagus | ESCC | 1.07e-21 | 6.12e-01 | 0.0889 |
51441 | YTHDF2 | P9T-E | Human | Esophagus | ESCC | 1.12e-16 | 2.65e-01 | 0.1131 |
51441 | YTHDF2 | P10T-E | Human | Esophagus | ESCC | 4.10e-45 | 1.21e+00 | 0.116 |
51441 | YTHDF2 | P11T-E | Human | Esophagus | ESCC | 1.61e-18 | 8.27e-01 | 0.1426 |
51441 | YTHDF2 | P12T-E | Human | Esophagus | ESCC | 3.74e-27 | 8.94e-01 | 0.1122 |
51441 | YTHDF2 | P15T-E | Human | Esophagus | ESCC | 5.89e-38 | 1.12e+00 | 0.1149 |
51441 | YTHDF2 | P16T-E | Human | Esophagus | ESCC | 3.34e-33 | 7.86e-01 | 0.1153 |
51441 | YTHDF2 | P17T-E | Human | Esophagus | ESCC | 7.79e-05 | 6.52e-01 | 0.1278 |
51441 | YTHDF2 | P19T-E | Human | Esophagus | ESCC | 2.57e-06 | 5.73e-01 | 0.1662 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00603384 | Oral cavity | OSCC | regulation of type I interferon-mediated signaling pathway | 28/7305 | 36/18723 | 2.45e-06 | 3.08e-05 | 28 |
GO:00607594 | Oral cavity | OSCC | regulation of response to cytokine stimulus | 92/7305 | 162/18723 | 3.25e-06 | 3.90e-05 | 92 |
GO:00028324 | Oral cavity | OSCC | negative regulation of response to biotic stimulus | 65/7305 | 108/18723 | 6.62e-06 | 7.29e-05 | 65 |
GO:00450884 | Oral cavity | OSCC | regulation of innate immune response | 116/7305 | 218/18723 | 1.36e-05 | 1.37e-04 | 116 |
GO:00340637 | Oral cavity | OSCC | stress granule assembly | 21/7305 | 26/18723 | 1.66e-05 | 1.64e-04 | 21 |
GO:002240718 | Oral cavity | OSCC | regulation of cell-cell adhesion | 218/7305 | 448/18723 | 1.71e-05 | 1.68e-04 | 218 |
GO:00459482 | Oral cavity | OSCC | positive regulation of translational initiation | 23/7305 | 30/18723 | 3.05e-05 | 2.79e-04 | 23 |
GO:00507679 | Oral cavity | OSCC | regulation of neurogenesis | 179/7305 | 364/18723 | 4.49e-05 | 3.84e-04 | 179 |
GO:00072196 | Oral cavity | OSCC | Notch signaling pathway | 92/7305 | 172/18723 | 7.84e-05 | 6.08e-04 | 92 |
GO:00192214 | Oral cavity | OSCC | cytokine-mediated signaling pathway | 222/7305 | 472/18723 | 2.02e-04 | 1.35e-03 | 222 |
GO:000268310 | Oral cavity | OSCC | negative regulation of immune system process | 204/7305 | 434/18723 | 3.72e-04 | 2.27e-03 | 204 |
GO:00085934 | Oral cavity | OSCC | regulation of Notch signaling pathway | 53/7305 | 95/18723 | 6.64e-04 | 3.72e-03 | 53 |
GO:00519605 | Oral cavity | OSCC | regulation of nervous system development | 205/7305 | 443/18723 | 9.80e-04 | 5.11e-03 | 205 |
GO:00071629 | Oral cavity | OSCC | negative regulation of cell adhesion | 145/7305 | 303/18723 | 9.95e-04 | 5.18e-03 | 145 |
GO:00458244 | Oral cavity | OSCC | negative regulation of innate immune response | 41/7305 | 71/18723 | 1.05e-03 | 5.40e-03 | 41 |
GO:00507774 | Oral cavity | OSCC | negative regulation of immune response | 97/7305 | 194/18723 | 1.16e-03 | 5.91e-03 | 97 |
GO:0060339 | Oral cavity | OSCC | negative regulation of type I interferon-mediated signaling pathway | 15/7305 | 20/18723 | 1.19e-03 | 5.99e-03 | 15 |
GO:00342495 | Oral cavity | OSCC | negative regulation of cellular amide metabolic process | 130/7305 | 273/18723 | 2.20e-03 | 1.00e-02 | 130 |
GO:20007364 | Oral cavity | OSCC | regulation of stem cell differentiation | 33/7305 | 58/18723 | 4.32e-03 | 1.75e-02 | 33 |
GO:20007374 | Oral cavity | OSCC | negative regulation of stem cell differentiation | 15/7305 | 23/18723 | 9.84e-03 | 3.46e-02 | 15 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
YTHDF2 | insertion | Nonsense_Mutation | novel | c.551_552insATGACCTGTGCATGTAGAAACTTGTTTGA | p.Ile185Ter | p.I185* | Q9Y5A9 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
YTHDF2 | SNV | Missense_Mutation | rs528989825 | c.410A>G | p.Asn137Ser | p.N137S | Q9Y5A9 | protein_coding | tolerated(1) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
YTHDF2 | SNV | Missense_Mutation | novel | c.1608G>T | p.Lys536Asn | p.K536N | Q9Y5A9 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
YTHDF2 | SNV | Missense_Mutation | c.91N>A | p.Asp31Asn | p.D31N | Q9Y5A9 | protein_coding | tolerated(0.11) | possibly_damaging(0.578) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
YTHDF2 | SNV | Missense_Mutation | novel | c.188C>G | p.Ser63Cys | p.S63C | Q9Y5A9 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
YTHDF2 | insertion | Frame_Shift_Ins | novel | c.508_509insACGTCGCAGAA | p.Ala170AspfsTer17 | p.A170Dfs*17 | Q9Y5A9 | protein_coding | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD | ||
YTHDF2 | SNV | Missense_Mutation | c.1274G>A | p.Arg425His | p.R425H | Q9Y5A9 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
YTHDF2 | SNV | Missense_Mutation | c.850G>A | p.Val284Ile | p.V284I | Q9Y5A9 | protein_coding | tolerated(0.11) | benign(0.014) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
YTHDF2 | SNV | Missense_Mutation | c.1683N>T | p.Glu561Asp | p.E561D | Q9Y5A9 | protein_coding | deleterious(0) | probably_damaging(0.925) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
YTHDF2 | SNV | Missense_Mutation | rs775516240 | c.1408G>A | p.Val470Met | p.V470M | Q9Y5A9 | protein_coding | tolerated(0.47) | possibly_damaging(0.902) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |